

June 01, 2015

Facility	Amount (Rs. Crore)	Rating
Proposed Cash Credit	6.00	SMERA B-/ Stable (Assigned)

SMERA has assigned a rating of '**SMERA B-**' (read as **SMERA single B minus**) to the Rs.6.00 crore proposed long-term (fund based) bank facility of Kothari Medical & Surgicals (KMS). The outlook on the rating is '**Stable**'. The rating is constrained by the firm's small-scale operations in an intensely competitive segment of the pharmaceutical industry. The rating is also constrained by the diversion of funds from the firm. The rating factors the risk of capital withdrawal by proprietor. However, the rating draws comfort from the firm's experienced management.

KMS, established in 1999, is a Pune-based proprietorship firm engaged in trading of pharmaceutical products. KMS has small-scale operations marked by revenue of Rs.4.69 crore in FY2013-14 (refers to financial year, April 01 to March 31). The firm operates in an intensely competitive segment of the pharmaceutical industry. KMS has moderate capital base of Rs.0.99 crore as on March 31, 2014. The firm has made investments outside business and has given loan to affiliates aggregating to Rs.2.00 crore. KMS's financial profile is susceptible to withdrawal of capital by proprietor.

KMS benefits from its experienced management. Mr. Mahesh Kothari, proprietor of KMS, has around 15 years of experience in the firm's line of business.

Outlook: Stable

KMS's rating has a 'Stable' outlook. The outlook may be revised to 'Positive' in case the firm registers strong growth in revenues while achieving sustained improvement in profit margins and financial risk profile. Conversely, the outlook may be revised to 'Negative' in case of decline in the firm's revenue and profit margins, or in case of deterioration in the firm's financial risk profile.

About the firm

KMS, established in 1999, is a Pune-based proprietorship firm promoted by Mr. Mahesh Kothari. KMS is engaged in trading of pharmaceutical products.

For FY2013-14, KMS reported profit before tax of Rs.0.28 crore on operating income of Rs.4.69 crore, as compared with profit before tax of Rs.0.29 crore on operating income of Rs.4.08 crore in FY2012-13. The firm registered revenue of ~Rs.7.50 crore (provisional) during FY2014-15. KMS's capital stood at Rs.0.99 crore as on March 31, 2014, as compared with Rs.0.75 crore a year earlier.

Disclaimer: A SMERA rating does not constitute an audit of the rated entity and should not be treated as a recommendation or opinion that is intended to substitute for a financial adviser's or investor's independent assessment of whether to buy, sell or hold any security. SMERA ratings are based on the data and information provided by the issuer and obtained from other reliable sources. Although reasonable care has been taken to ensure that the data and information is true, SMERA, in particular, makes no representation or warranty, expressed or implied with respect to the adequacy, accuracy or completeness of the information relied upon. SMERA is not responsible for any errors or omissions and especially states that it has no financial liability whatsoever for any direct, indirect or consequential loss of any kind arising from the use of its ratings. SMERA ratings are subject to a process of surveillance which may lead to a revision in ratings as and when the circumstances so warrant. Please visit our website (www.smera.in) for the latest information on any instrument rated by SMERA.



SMERA RATINGS LIMITED

Kothari Medical & Surgicals (KMS)

*Rating
Rationale***Contact List:**

Media / Business Development	Analytical Contacts	Rating Desk
Antony Jose Vice President – Business Development, Mid Corporate Tel: +91-22-6714 1191 Cell: +91 98208 02479 Email: antony.jose@smera.in	Shripad Nande Manager - Corporate Ratings Tel: +91-22-6714 1329 Email: shripad.nande@smera.in	Tel: +91-22-6714 1184 Email: ratingdesk@smera.in

Disclaimer: A SMERA rating does not constitute an audit of the rated entity and should not be treated as a recommendation or opinion that is intended to substitute for a financial adviser's or investor's independent assessment of whether to buy, sell or hold any security. SMERA ratings are based on the data and information provided by the issuer and obtained from other reliable sources. Although reasonable care has been taken to ensure that the data and information is true, SMERA, in particular, makes no representation or warranty, expressed or implied with respect to the adequacy, accuracy or completeness of the information relied upon. SMERA is not responsible for any errors or omissions and especially states that it has no financial liability whatsoever for any direct, indirect or consequential loss of any kind arising from the use of its ratings. SMERA ratings are subject to a process of surveillance which may lead to a revision in ratings as and when the circumstances so warrant. Please visit our website (www.smera.in) for the latest information on any instrument rated by SMERA.